Free Trial
NYSE:KDMN

Kadmon (KDMN) Stock Price, News & Analysis

→ This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad)
Free KDMN Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$9.50
▼
$9.50
50-Day Range
$9.50
▼
$9.50
52-Week Range
$3.19
▼
$9.50
Volume
1,052 shs
Average Volume
5.11 million shs
Market Capitalization
$1.70 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
KDMN stock logo

About Kadmon Stock (NYSE:KDMN)

Kadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Its clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies.

KDMN Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com
Receive KDMN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kadmon and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
Sub-Industry
N/A
Current Symbol
NYSE:KDMN
CUSIP
N/A
CIK
N/A
Web
N/A
Phone
12123086000
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
178,521,000
Free Float
N/A
Market Cap
$1.70 billion
Optionable
Optionable
Beta
N/A
12 Stocks Corporate Insiders are Abandoning Cover
12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

KDMN Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Kadmon own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kadmon investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Organigram (OGI), KushCo (KSHB), Gran Tierra Energy (GTE), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), Pennsylvania Real Estate Investment Trust (PEI), Auxly Cannabis Group (CBWTF) and CNBX Pharmaceuticals (CNBX).

When did Kadmon IPO?

Kadmon (KDMN) raised $101 million in an initial public offering on Wednesday, July 27th 2016. The company issued 5,600,000 shares at $16.00-$20.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and JMP Securities and H.C. Wainwright & Co. were co-managers.

This page (NYSE:KDMN) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners
Pentagon contract could send this $2 AI stock soaring
Behind the Markets
The A.I. story nobody is telling you (Read ASAP)
TradeSmith
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
This Apple-like Innovator is Revolutionizing Healthcare
Wall Street Star
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
Traders Agency
Did You Get Your Free Bitcoin Yet?
Crypto Swap Profits
Urgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!
American Alternative
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press